Board of Directors

Naruhito Higo headshotDR. NARUHITO HIGO

Board Chairman

Chief Executive Officer
Noven Pharmaceuticals, Inc.

Hisamitsu Pharmaceutical Co., Inc.

Toshiaki Tsuruda HeadshotTOSHIAKI TSURUDA

Vice Chairman

Director and Executive Officer and Head of Production Division
Hisamitsu Pharmaceutical Co., Inc.

Noven Officers



Chairman & Chief Executive Officer

Dr. Naruhito Higo serves as Noven’s Chairman and Chief Executive Officer. He has been with Hisamitsu Pharmaceutical Co., Inc. since 1985, and served as the Head of Research and Development from 2007 to 2017. Dr. Higo has been a member of Hisamitsu’s Board of Directors since 2012 and was appointed as Chairman of Noven’s Board of Directors in 2017. Dr. Higo earned his PhD in Pharmaceutical Science from Kumamoto University in Japan. His rich history with Hisamitsu, his role as Chairman of the Board for Noven, and his vision for future Noven/Hisamitsu strategy position him as an ideal choice to lead Noven in advancing our mission of benefiting patients around the world with transdermal drug delivery systems.



Chief Operating Officer & Chief Medical Officer

Dr. Joel Lippman is Noven’s Chief Operating Officer and Chief Medical Officer. He is an obstetrician-gynecologist certified by the American Board of Obstetrics and Gynecology with nearly 30 years' experience in research and development, clinical development, and medical affairs in the pharmaceutical and medical device industries. Dr. Lippman previously served as Noven’s Executive Vice President – Product Development & Chief Medical Officer from 2008 through 2016.  Prior to joining Noven, Dr. Lippman served as Worldwide Vice President – Medical Affairs & Chief Medical Officer and a member of the Global Management Board at Ethicon, Inc., a Johnson & Johnson company. Earlier, he served as Vice President – Clinical Trials at Ortho-McNeil Pharmaceutical, Inc., also a Johnson & Johnson company, and held a number of clinical development, medical affairs, and related roles at Wyeth-Ayerst Laboratories. Dr. Lippman holds a Medical Degree from New York Medical College and a Masters in Public Health from Harvard University School of Public Health, and is a Fellow of the American College of Obstetricians and Gynecologists.



Senior Vice President – Quality & Operations

Mark Jackson is Noven’s Sr. Vice President – Quality & Operations, having previously served as Noven’s Vice President – Quality and Vice President – Quality & Operations.  Mr. Jackson has over 30 years’ experience in the pharmaceutical and medical device industries. He joined Noven from HeartWare, Inc., a global medical device company specializing in the treatment of heart failure, where he served as the Vice President of Quality and Design Assurance. Previously, Mr. Jackson was at Baxter Healthcare Corp where he held positions of increasing responsibility including Vice President Medical Products Quality, Vice President Quality, Renal Division/Global Technical Service, and Plant Manager.

JOHN CHOI Headshot


Vice President, Chief Financial Officer & Treasurer

John Choi is Noven’s Vice President, Chief Financial Officer, and Treasurer.  Mr. Choi, who joined Noven in 2010, most recently served Noven as its Executive Director – Business Planning & Analysis. Prior to Noven, Mr. Choi served as Director of Commercial Operations & Planning for Ther-Rx (a branded pharmaceutical division of KV Pharmaceuticals). Previously, he served Abbott Laboratories in various positions in the manufacturing operations, cost accounting, finance, and international divisions, and served as an expatriate at Abbott’s Korean affiliate, where he held leadership roles in financial planning and analysis and other commercial leadership roles.



Vice President, General Counsel & Corporate Secretary

Michael Greene is Noven’s Vice President, General Counsel, and Corporate Secretary. Mr. Greene previously served as Noven’s Deputy General Counsel & Executive Director – Alliance Management. From 2005 to 2010, Mr. Greene was an attorney at the law firm of Paul, Hastings, Janofsky & Walker, where he specialized in mergers and acquisitions (M&A) and other complex corporate transactions, including pharmaceutical industry transactions. Previously, he was an attorney with the law firm of Hunton & Williams specializing in M&A transactions and corporate law.



Vice President – Hisamitsu Group Strategy & Planning

Shinichi Sato is Noven’s Vice President, Hisamitsu Group Strategy & Planning. He joined Noven in May 2019. He has over 21 years’ experience in the pharmaceutical industry. Previously, he served Hisamitsu Pharmaceutical Co., Inc. in a variety of functions including Corporate Planning, Investor Relations, President's office, and Marketing & Sales. He earned an MBA from Graduate School of Business Administration, Keio University in Japan.

Fast Facts

Core Business:
Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:

Over 300

Chairman &
Chief Executive Officer:

Dr. Naruhito Higo

Media, General Business
& Other Inquiries:


Partnering and Other Business Development Opportunities
Tel: 551-233-2700

Physican Payment
Sunshine Act Inquiries:


Employment Inquiries:
Rory Kelly
Associate Director – Recruiting

Community Support:
Corporate Social Responsibility

Affiliated Companies:
Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.

Noven's commercialized products are marketed and sold through Noven Therapeutics, LLC.

Grove Pharmaceuticals is the generic division of Noven Therapeutics, LLC.